Phase II trial weekly biweekly intraperitoneal mitoxantrone epithelial ovarian cancer Previous experimental clinical evaluation ovarian cancer sensitive cytotoxic effects mitoxantrone concentrations achievable peritoneal cavity intraperitoneal IP administration use drug IP high doses normal saline NS monthly schedule severe local effects secondary irritant properties drug toxicity advantage minimal systemic drug exposure IP administration patients drug concentration mitoxantrone NS weekly week schedule total courses monthly program regimen pain cumulative dose mitoxantrone serious treatment-related morbidity assessable patients tumor equal cm diameter response patients minimal response improved toxicity profile regimen overall response rate similar monthly program secondary IP drug distribution many patients Future investigative efforts IP mitoxantrone therapy ovarian cancer methods drug delivery sites tumor peritoneal cavity eg intraoperative therapy treatment volumes antiinflammatory agents adhesion formation 